Onclive Team

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Patients with untreated or relapsed/refractory chronic lymphocytic leukemia achieved durable responses with single-agent ibrutinib (Imbruvica).

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

John R. Seffrin, PhD, who was honored with a 2014 Giants of Cancer Care® award, has spent his career helping to advance cancer prevention through education and public policy initiatives as a volunteer and as a longtime leader at the American Cancer Society.

The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant non–small cell lung cancer following resistance to frontline anti-EGFR therapy.

Ten-story building named for Albert P. "Skip" Viragh Jr. planned for the northeast corner of Fayette Street and North Broadway.

Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative non­–small cell lung cancer.

Jeffrey S. Weber, MD, PhD, to serve as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, Co-Director of its Melanoma Program and Head of Experimental Therapeutics.

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

OncLive today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital's pioneering research and care for cancer patients. Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

Young women with breast cancer may decline, discontinue tamoxifen because of fertility concerns.

Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world's most prevalent and lethal forms of cancer.

A huge amount of training and preparation has preceded the October 1 implementation of International Classification of Diseases, Tenth Revision (ICD-10).

Fox Chase Cancer Center's breast cancer program has earned full accreditation for the third time from The National Accreditation Program for Breast Centers.

Data collection has to be improved in order for physicians to be able to convince payers to support certain types of costly therapy, a panel of physicians.

Alliance will share news about research and supportive care services.

117-year-old facility is only comprehensive cancer center in Upstate New York

Andrew S. Chi, MD, PhD, has also been appointed co-director of the NYU Langone Brain Tumor Center.

Immunotherapy for the treatment of cancer has evolved alongside our improved understanding of the immune system.

Howard A. "Skip" Burris III, MD, has helped launched many widely used anticancer therapies by designing and helping to implement first-in-human studies and by leading advanced clinical trials of promising drugs. He was honored in the Drug Development category with a 2014 Giants of Cancer Care® award.

Results from clinical trials demonstrate that immunotherapy is ready to take center stage in the fight against bladder cancer.

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

Emerging clinical data suggest that targeted immunotherapy in cancer will become an integral part of the clinical management strategy for solid tumors.

OncLive  editorial, marketing teams will share news about Sylvester Center.

Advances in the field of immunotherapy and targeted therapy have brought about new recommendations for patients with melanoma.

William F. Elmquist, PharmD, PhD, discusses the impact of the blood-brain barrier upon the effectiveness of anticancer therapies.

OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive's Strategic Alliance Partnership program.